<DOC>
	<DOC>NCT00938314</DOC>
	<brief_summary>The purpose of this study is: - To assess the neurological outcome in acute ischemic stroke patients treated with NTx®-265, when compared with patients given a placebo control. - To assess the safety and tolerability of NTx®-265 when given to acute ischemic stroke patients.</brief_summary>
	<brief_title>Study of NTx®-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients</brief_title>
	<detailed_description />
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Chorionic Gonadotropin</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Age 1885 NIHSS score 820 Stroke is ischemic in origin, supratentorial, and radiologically confirmed Patient is 2448 hours from time of stroke onset when the first dose of NTx®265 therapy is administered Reasonable expectation of availability to receive the full 9 day NTx® 265 therapy and subsequent followup visits Reasonable expectation that patient will receive standard poststroke physical, occupational, speech, and cognitive therapy as indicated Female patient is either not of childbearing potential or agrees to use two of the effective separate nonhormonal forms of contraception throughout the study Patients presenting with lacunar, hemorrhagic and/or brain stem stroke Patients who have received tissue plasminogen activator (tPA)following the index stroke Patients classified as comatose Women who have tested positive for pregnancy, or are breastfeeding, or are not using a birth control Serum hemoglobin &gt; 16 grams(g)/deciliter (dL)(males) or &gt; 14 g/dL (females); or platelet count &gt; 400,000/cubic millimeters(mm3) Advanced liver, kidney, cardiac, or pulmonary disease Elevated serum bilirubin,alkaline phosphatase, aspartate aminotransferase (AST) or alanine transaminase (ALT),creatinine, or prostatespecific antigen (PSA) levels Patients with a known history of hypercoagulability Expected survival &lt; 1 year Allergy or other contraindication to hCG or EPO A known diagnosis of cancer in the previous 5 years Uncontrolled hypertension Use of either hCG or epoetin alfa within the previous 90 days Any condition known to elevate hCG Patients with a prestroke/premorbid modified Rankin Score (mRS)≥ 2 Any patients not living independently Any other medical condition or degree of stroke such that, in the investigator's opinion, the patient should not be included in the trial With the exception of the qualifying stroke, any other stroke within the previous 3 months Patients who cannot take antiplatelet or anticoagulant therapy Preexisting and active major psychiatric or other chronic neurological disease Alcohol abuse or have a history of substance abuse or dependency within 12 months prior to the study Currently participating in another investigational study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2011</verification_date>
</DOC>